JPM Day 2 has arrived. Here are the can’t-miss moments of the event so far

In honor of JPM Week, you’re reading a special edition of our biotech newsletter, The Readout. To stay on top of the latest scoops and live reporting from the San Francisco conference, join our newsletter list.

After a one-day respite from JPM tradition, the rain returned this morning, leading to some dampened spirits and at least one canny promotional effort. (We’ve still got plenty of STAT-branded umbrellas at our coworking space, if you’re in need.) Anyway, here are the highlights from Day 2.

Will Sarepta earn a participation trophy from the FDA?

Sure seems like it, based on remarks made by Peter Marks, the agency’s chief gene therapy regulator, at STAT’s event on Monday night. By trophy, we mean full approval of some kind for Elevidys, Sarepta Therapeutics’ treatment for Duchenne muscular dystrophy.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $399/year

$30 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In